Collaboration Deals in Pharmaceuticals 2021-2026

Understand how pharmaceutical companies structure collaboration partnerships to access innovation, share development risk and combine complementary capabilities.

Collaboration Deals in Pharmaceuticals provides comprehensive intelligence on 1,404 collaboration deals involving pharmaceutical companies.

The report examines how pharmaceutical companies use collaboration agreements to access technologies, capabilities and development opportunities, work with external partners and advance assets through research, development and commercialization.

Rather than simply identifying transactions, the report enables users to understand who is collaborating, where deal activity is concentrated, how agreements are structured, and what can be learned from disclosed financial terms and publicly available contract documents.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, alliance management and legal teams involved in evaluating or negotiating pharmaceutical collaborations.

Understand the pharmaceutical collaboration landscape

The report analyzes collaboration dealmaking from 2021 to 2026, including:

• Trends in collaboration dealmaking by year
• Stage of development at the time of partnering
• Industry sector
• Therapy area
• Technology type
• Most active collaboration dealmakers
• Leading deals by disclosed value
• Strategic reasons for entering collaboration agreements
• How pharmaceutical collaboration strategies are evolving
• This provides a clear view of where collaboration activity is concentrated and how pharmaceutical companies are using external partnerships across different technologies, therapeutic areas and stages of development.
• Understand how collaboration agreements are structured
• Collaboration agreements can encompass a wide range of research, development and commercialization relationships.

The report provides intelligence to help users examine areas including:

• Research and development responsibilities
• Rights granted or optioned
• Development funding and cost allocation
• Intellectual property ownership and rights
• Governance and decision-making
• Exclusivity provisions
• Development and regulatory responsibilities
• Manufacturing and supply
• Commercialization rights and responsibilities
• Geographic and market rights
• Financial terms where disclosed
• Term and termination provisions
• This provides useful reference points for teams assessing potential collaboration models or preparing for partnering discussions.
• Benchmark leading deals and disclosed financial terms
• The report identifies leading pharmaceutical collaboration transactions by disclosed deal value and provides access to available financial information associated with individual agreements.

Users can investigate disclosed elements including:

• Upfront payments
• Development and regulatory milestones
• Commercial milestones
• Royalty arrangements
• Equity components
• Other financial commitments where available
• This helps users place potential transactions into the context of comparable real-world collaborations and develop more informed positions ahead of deal discussions.
• Identify leading collaboration dealmakers
• The report profiles the Top 25 most active collaboration dealmakers, providing insight into the pharmaceutical and biotechnology companies most frequently entering collaborative partnerships.

Individual deal histories can help users understand how particular companies approach external innovation and support:

• Partner identification
• Search and evaluation
• Competitor analysis
• Business development strategy
• Assessment of partnering behaviour
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying collaboration contract documents.
• These agreements can reveal substantially more detail than company announcements alone, enabling users to examine how selected partners have addressed areas such as development obligations, intellectual property, exclusivity, governance, financial arrangements, commercialization rights and termination.
• For teams preparing for or negotiating collaboration agreements, these real-world contracts provide valuable insight into how comparable transactions have been documented in practice.
• Comprehensive collaboration deal directory
• The report includes a comprehensive directory of 1,404 pharmaceutical collaboration deals, enabling users to identify transactions relevant to their own assets, technologies and partnering objectives.

Deals can be reviewed by:

• Company
• Therapy area
• Technology type
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable deals, potential partners and relevant structures when evaluating or preparing pharmaceutical collaborations.
• Search and Evaluation teams
• Understand which companies are partnering in specific technology, therapy and development areas and investigate their previous transaction activity.
• Corporate and R&D Strategy teams
• Track how pharmaceutical companies are using external collaborations to access innovation and complement internal development capabilities.
• Alliance Management teams
• Examine how development responsibilities, governance and ongoing partner obligations have been structured across comparable agreements.
• Legal and Transaction teams
• Review deal structures and publicly available contract language to support transaction preparation and negotiation.
• Competitive and Market Intelligence teams
• Analyze collaboration activity by company, therapy area, technology and development stage to identify important partnering trends.
• Turn market-wide intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying collaboration intelligence to the customer's own business, assets, technologies or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, deal structures, financial benchmarks, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.